Research map: Guideline on treatment intensification with injectable therapies beyond GLP-1 RA based therapies in type 2 diabetes

Back to the article

Papers in this map

  1. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes · Steven P. Marso · 2016 · 6910 citations · Cited by this paper
  2. Telehealth effectiveness for glycaemic control of older adults with Type 2 diabetes: An integrative review · 2026 · Related
  3. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) · Melanie J. Davies · 2022 · 2106 citations · Cited by this paper
  4. Burden of type 2 diabetes attributable to dietary risks in 34 Asian countries: the Global Burden of Disease Study 2023 · 2026 · Related
  5. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes · Juan P. Frías · 2021 · 2036 citations · Cited by this paper
  6. Cardiorenal-metabolic phenotypes and risks of mortality and cardiovascular outcomes in type 2 diabetes: a retrospective cohort study · 2026 · Related
  7. Guidelines International Network: Principles for Disclosure of Interests and Management of Conflicts in Guidelines · Holger Jens Schünemann · 2015 · 345 citations · Cited by this paper
  8. U-500 regular insulin in automated insulin delivery systems for severe insulin resistance: A single-center retrospective cohort · 2026 · Related
  9. Ein Instrument zur Erstellung von Leitlinienberichten: das RIGHT-Statement · Yaolong Chen · 2017 · 179 citations · Cited by this paper
  10. Consensus Recommendations on Lipohypertrophy: Insights From an International Panel of Experts · 2026 · Related
  11. The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial · Sultan Linjawi · 2016 · 136 citations · Cited by this paper
  12. One-hour glucose–defined metabolic phenotypes in youth with obesity: early β-cell impairment across the spectrum of dysglycemia · 2026 · Related
  13. Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial · Lawrence Blonde · 2019 · 84 citations · Cited by this paper
  14. Predicted risk of death and frequency of outpatient follow-up visits in diabetes clinics. Insight from the large, real-life Italian AMD-Annals database · 2026 · Related
  15. A Comparison of AGREE and RIGHT: which Clinical Practice Guideline Reporting Checklist Should Be Followed by Guideline Developers? · Xiaomei Yao · 2019 · 51 citations · Cited by this paper
  16. Comparative dementia risk associated with SGLT2 inhibitors versus DPP-4 inhibitors in patients with type 2 diabetes following traumatic brain injury: A propensity score–matched Cohort study · 2026 · Related
  17. Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial · Takahiro Takase · 2018 · 48 citations · Cited by this paper
  18. Serum vs. exosomal miRNA signatures in South Asian adults with prediabetes: implications for T2DM risk prediction · 2026 · Related
  19. One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target · Julio Rosenstock · 2013 · 46 citations · Cited by this paper
  20. Heterogeneity in type 2 diabetes onset across combinations of lifestyle behaviours in the UK Biobank · 2026 · Related
  21. Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double‐blind randomized controlled trial ( BEGIN : ADD TO GLP ‐1 S tudy) · Vanita R. Aroda · 2016 · 33 citations · Cited by this paper
  22. Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial · Ildiko Lingvay · 2025 · 27 citations · Cited by this paper
  23. Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin · Lawrence Blonde · 2018 · 23 citations · Cited by this paper
  24. Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide · Liana K. Billings · 2025 · 18 citations · Cited by this paper
  25. Real-world use of glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes: A retrospective database study (DEFINE-G) · Mitsuru Ohsugi · 2023 · 15 citations · Cited by this paper
  26. Comparison of Effects of Injectable Semaglutide and Dulaglutide on Oxidative Stress and Glucose Variability in Patients with Type 2 Diabetes Mellitus: A Prospective Preliminary Study · Takemasa Omachi · 2023 · 10 citations · Cited by this paper
  27. GRADE notes 6: Three strategies to determine the clinically important thresholds for outcomes in evidence-based guideline development · Xiaomei Yao · 2025 · 7 citations · Cited by this paper
  28. Effectiveness, safety, initial optimal dose, and optimal maintenance dose range of basal insulin regimens for type 2 diabetes: A systematic review with meta‐analysis · Yingying Luo · 2023 · 6 citations · Cited by this paper
  29. Use of basal insulin in the management of adults with type 2 diabetes: An Asia‐Pacific evidence‐based clinical practice guideline · Linong Ji · 2023 · 5 citations · Cited by this paper
  30. Untitled · Cited by this paper

Source: OpenAlex (CC0)